Genmab A (GMAB) Accounts Payables (2023 - 2025)

Genmab A (GMAB) has reported Accounts Payables for 3 consecutive years, with $145.0 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 141.99% year-over-year to $145.0 million; the trailing twelve-month figure through Dec 2025 stood at $145.0 million (up 141.99% YoY), and the FY2025 full-year result was $145.0 million, up 141.99% from the prior year.
• Accounts Payables grew to $145.0 million in Q4 2025 per GMAB's latest filing, from $59.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $145.0 million in Q4 2025 and bottomed at $31.0 million in Q4 2023.
• Historically, Accounts Payables has averaged $78.6 million across 3 years, with a median of $59.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables surged 93.28% in 2024, then surged 141.99% in 2025.
• Over 3 years, Accounts Payables stood at $31.0 million in 2023, then soared by 93.28% to $59.9 million in 2024, then soared by 141.99% to $145.0 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $145.0 million, $59.9 million, and $31.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.